Eltrombopag: An oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura

Clinical Therapeutics

Volumn 33, Issue 11, 2011, Pages 1560-1576

  Zhang, Yang ^a   Kolesar, Jill M ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Eltrombopag; ITP

Indexed keywords

AMIODARONE; ANTACID AGENT; ATORVASTATIN; CAFFEINE; CARBOPLATIN; CELECOXIB; CIPROFLOXACIN; ELTROMBOPAG; FLURBIPROFEN; GEMCITABINE; LEVOTHYROXINE; METHOTREXATE; MIDAZOLAM; OMEPRAZOLE; PACLITAXEL; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PIOGLITAZONE; PLACEBO; RECOMBINANT INTERLEUKIN 11; RIBAVIRIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TAMOXIFEN; UNINDEXED DRUG; VALSARTAN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTHRALGIA; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOPULMONARY INSUFFICIENCY; CATARACT; COCHRANE LIBRARY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FOOD; HEADACHE; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIPID DIET; LIVER CIRRHOSIS; LIVER TOXICITY; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MEDLINE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NAUSEA; OVARY CANCER; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

BENZOIC ACIDS; DRUG INTERACTIONS; HUMANS; HYDRAZINES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, THROMBOPOIETIN;

EID: 82855166068     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.004     Document Type: Review

References (63)

1. Stasi R., Evangelista M.L., Stipa E., et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008, 99:4-13.
2. Corman S.L., Mohammad R.A. Eltrombopag: a novel oral thrombopoietin receptor agonist. Ann Pharmacother 2010, 44:1072-1079.
3. Kuter D.J. New thrombopoietic growth factors. Blood 2007, 109:4607-4616.
4. Segal J.B., Powe N.R. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006, 4:2377-2383.
5. Cines D.B., Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med 2002, 346:995-1008.
6. Stasi R., Stipa E., Masi M., et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995, 98:436-442.
7. Kuhne T., Imbach P., Bolton-Maggs P.H., et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 2001, 358:2122-2125.
8. Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115:168-186.
9. Nurden A.T., Viallard J.F., Nurden P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet 2009, 373:1562-1569.
10. Zaja F., Baccarani M., Mazza P., et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010, 115:2755-2762.
11. Kuter D.J. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 2009, 60:193-206.
12. Basser R.L., Rasko J.E., Clarke K., et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997, 89:3118-3128.
13. Fanucchi M., Glaspy J., Crawford J., et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997, 336:404-409.
14. Nomura S., Dan K., Hotta T., et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002, 100:728-730.
15. Li J., Yang C., Xia Y., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
16. Chouhan J.D., Herrington J.D. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag. Pharmacotherapy 2010, 30:666-683.
17. Lam M.S. Review article: Second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults. J Oncol Pharm Pract 2010, 16:89-103.
18. PROMACTA (eltrombopag) [prescribing information] October 2009, GlaxoSmithKline, Research Triangle Park, NC, Accessed January 22, 2011. http://us.gsk.com/products/assets/us_promacta.pdf.
19. Jenkins J.M., Williams D., Deng Y., et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007, 109:4739-4741.
20. Kim M.J., Park S.H., Opella S.J., et al. NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains. J Biol Chem 2007, 282:14253-14261.
21. Bussel J.B., Pinheiro M.P. Eltrombopag. Cancer Treat Res 2011, 157:289-303.
22. Erickson-Miller C.L., Delorme E., Tian S.S., et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009, 27:424-430.
23. Erhardt J.A., Erickson-Miller C.L., Aivado M., et al. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009, 37:1030-1037.
24. Sellers T., Hart T., Semanik M., Murthy K. Pharmacology and safety of SB-497115-GR, an orally active small molecular weight TPO receptor agnoist, in chimpanzees, rats and dogs. Blood 2004, 104:568a.
25. Erickson-Miller C.L., DeLorme E., Tian S.S., et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005, 33:85-93.
26. Stasi R., Bosworth J., Rhodes E., et al. Thrombopoietic agents. Blood Rev 2010, 24:179-190.
27. Ezumi Y., Takayama H., Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett 1995, 374:48-52.
28. Kojima H., Hamazaki Y., Nagata Y., et al. Modulation of platelet activation in vitro by thrombopoietin. Thromb Haemost 1995, 74:1541-1545.
29. Rodriguez-Linares B., Watson S.P. Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation. Biochem J 1996, 316(Pt 1):93-98.
30. Gibiansky E., Zhang J., Williams D., et al. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol 2011, 51:842-856.
31. Matthys G., Park J.W., McGuire S., et al. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers. J Clin Pharmacol 2011, 51:301-308.
32. Bussel J.B., Provan D., Shamsi T., et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:641-648.
33. Hayes S., Ouellet D., Zhang J., et al. Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. J Clin Pharmacol 2011, 51:1403-1417.
34. Lim J.S., Singh O., Ramasamy R.D., et al. Pharmacogenetics of CYP1A2, novel polymorphisms and haplotypes in three distinct Asian populations. Drug Metab Pharmacokinet 2011, 25:616-623.
35. Zhou Y.Y., Lee L.Y., Ng S.Y., et al. UGT1A1 haplotype mutation among Asians in Singapore. Neonatology 2009, 96:150-155.
36. Jada S.R., Lim R., Wong C.I., et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 2007, 98:1461-1467.
37. Zhang J., Williams D., Moore K. Use of eltrombopag exposure-platelet response relationship for dose optimization in patients with chronic HCV infection with and without interferon. Abstract presented at: 18th Population Approach Group in Europe (PAGE) June 23-26, 2009, Abstract 1494.
38. Bauman J.W., Vincent C.T., Peng B., et al. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics. J Clin Pharmacol 2011, 51:739-750.
39. Williams D.D., Peng B., Bailey C.K., et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther 2009, 31:764-776.
40. Jenkins J., Williams D., Deng Y., et al. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. Eur J Clin Pharmacol 2010, 66:67-76.
41. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007, 357:2237-2247.
42. Cheng G., Saleh M.N., Marcher C., et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011, 377:393-402.
43. Saleh M.N., Bussel J.B., Cheng G., et al. Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: results from the EXTEND study. Blood 2009, 114:285-286.
44. Bussel J.B., Psaila B., Saleh M.N., et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura. Blood 2008, 112:1176-1177.
45. Psaila B., Bussel J., Vasey S., et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura (Itp). Haematologica 2008, 93(Suppl 1). 120 Abs.0294.
46. Afdhal N., McHutchison J., Brown R., et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008, 48:1000-1007.
47. Dusheiko G. Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C. Clin Liver Dis 2009, 13:487-501.
48. McHutchison J.G., Dusheiko G., Shiffman M.L., et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007, 357:2227-2236.
49. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol 2009, 46(1 Suppl 2):S26-S32.
50. Kellum A., Jagiello-Gruszfeld A., Bondarenko I.N., et al. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin 2010, 26:2339-2346.
51. Bryan J., Jabbour E., Prescott H., Kantarjian H. Thrombocytopenia in patients with myelodysplastic syndromes. Semin Hematol 2010, 47:274-280.
52. Koehrer S., Keating M.J., Wierda W.G. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia 2010, 24:1096-1098.
53. Erickson-Miller C.L., Kirchner J., Aivado M., et al. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res 2010, 34:1224-1231.
54. Will B., Kawahara M., Luciano J.P., et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009, 114:3899-3908.
55. Mavroudi I., Pyrovolaki K., Pavlaki K., et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res 2011, 35:323-328.
56. Cuker A., Chiang E.Y., Cines D.B. Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia. Curr Drug Saf 2010, 5:171-181.
57. Harker L.A., Hunt P., Marzec U.M., et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996, 87:1833-1844.
58. Bowen C.J., Lobb K.M., Park J.W., et al. Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial. Photodermatol Photoimmunol Photomed 2010, 26:243-249.
59. Matthys G., Park J.W., McGuire S., et al. Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. Br J Clin Pharmacol 2010, 70:24-33.
60. Lexi-Comp Online Hudson, Ohio: Lexi-Comp, Inc., Accessed May, 2011. http://www.crlonline.com/crlsql/servlet/crlonline.
61. Serebruany V.L., Eisert C., Sabaeva E., Makarov L. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations. Am J Ther 2010, 17:68-74.
62. Burzynski J. New options after first-line therapy for chronic immune thrombocytopenic purpura. Am J Health Syst Pharm 2009, 66(2 Suppl 2):S11-S21.
63. Kuter D.J., Rummel M., Boccia R., et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010, 363:1889-1899.